BIOTECHNOLOGY, IMAGING, AND DRUG DEVELOPMENT PROGRAM ABSTRACT/PROJECT SUMMARY The overarching goal of the reorganized Biotechnology, Imaging, and Drug Development (BIDD) Program is to utilize novel computational, chemical, and engineering-based approaches to detect, diagnose, and treat cancer. The BIDD Program evolved in response to the increasingly interdisciplinary nature of cancer research, spanning chemistry, physics, mathematics, optics, engineering, biology, and medicine. The Program initiates concepts through cross-disciplinary meetings at the pre-design phases; progresses through technology development involving advanced chemistry, physics, and engineering; and proceeds through preclinical validation in model systems and tissues before testing in clinical trials. The BIDD Program fuses two prior complementary programs and provides leadership and structure to translate basic discoveries to the clinic. The formation of the Program synergistically combines UCI's strengths in synthetic chemistry, bioengineering, and physics to maximize translation of basic research. As the de facto technology development hub for the Cancer Center, BIDD reaches out to other Cancer Center programs, Catchment Area stakeholders, and the investment community to build interdisciplinary teams able to steer new technologies into cancer-relevant directions. The BIDD leadership facilitates this process by establishing interdisciplinary teams of clinicians, physical scientists, and biologists to guide each project from its earliest stages; assist in the design of validation experiments using appropriate models (animal models with the Transgenic Mouse Facility, TMF), human tissues through the Experimental Tissue Resource (ETR), and ex vivo tissue models); implement deep learning approaches for drug and diagnostics development; provide infrastructure to complete IND-enabling studies; and design clinical trials to test drug candidates and devices. Membership: 78 Members from 24 Departments and 6 Schools Funding: $3,003,969 NCI (Directs); $7,540,410 Other Peer-Reviewed (Directs) Accruals: Interventional: 272; Treatment: 169; Institutional/Investigator-Initiated: 166 Publications: Total: 542; High Impact Journal: 101 (19%); Intra-programmatic: 107 (20%); Inter-programmatic: 109 (20%); Inter-Institutional: 262 (48%)